139 related articles for article (PubMed ID: 14529791)
1. The impact of geometric uncertainty on hypofractionated external beam radiation therapy of prostate cancer.
Craig T; Moiseenko V; Battista J; Van Dyk J
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):833-42. PubMed ID: 14529791
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated proton therapy for prostate cancer: dose delivery uncertainty due to interfractional motion.
Wang Y; Efstathiou JA; Lu HM; Sharp GC; Trofimov A
Med Phys; 2013 Jul; 40(7):071714. PubMed ID: 23822418
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionation: what does it mean for prostate cancer treatment?
Liao Y; Joiner M; Huang Y; Burmeister J
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):260-8. PubMed ID: 19879698
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: a radiobiologic analysis.
Song WY; Schaly B; Bauman G; Battista JJ; Van Dyk J
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):289-300. PubMed ID: 16377417
[TBL] [Abstract][Full Text] [Related]
5. Influence of SBRT fractionation on TCP and NTCP estimations for prostate cancer.
Sukhikh ES; Sukhikh LG; Taletsky AV; Vertinsky AV; Izhevsky PV; Sheino IN
Phys Med; 2019 Jun; 62():41-46. PubMed ID: 31153397
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
Ödén J; Eriksson K; Toma-Dasu I
Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
[TBL] [Abstract][Full Text] [Related]
7. Impact of geometric uncertainties on evaluation of treatment techniques for prostate cancer.
Craig T; Wong E; Bauman G; Battista J; Van Dyk J
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):426-36. PubMed ID: 15890584
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer.
Amer AM; Mott J; Mackay RI; Williams PC; Livsey J; Logue JP; Hendry JH
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):199-207. PubMed ID: 12694839
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
11. What hypofractionated protocols should be tested for prostate cancer?
Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
[TBL] [Abstract][Full Text] [Related]
12. Limitations of a convolution method for modeling geometric uncertainties in radiation therapy: the radiobiological dose-per-fraction effect.
Song W; Battista J; Van Dyk J
Med Phys; 2004 Nov; 31(11):3034-45. PubMed ID: 15587657
[TBL] [Abstract][Full Text] [Related]
13. MO-A-213AB-09: Hypofractionated Proton Therapy of the Prostate: The Impact of the Uncertainties in Dose Delivery and Alpha/Beta Ratio on Tumor Dose Escalation.
Wang Y; Trofimov A
Med Phys; 2012 Jun; 39(6Part20):3860-3861. PubMed ID: 28517512
[TBL] [Abstract][Full Text] [Related]
14. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer.
Strigari L; Arcangeli G; Arcangeli S; Benassi M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1454-60. PubMed ID: 18990503
[TBL] [Abstract][Full Text] [Related]
15. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
16. A numerical simulation of organ motion and daily setup uncertainties: implications for radiation therapy.
Killoran JH; Kooy HM; Gladstone DJ; Welte FJ; Beard CJ
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):213-21. PubMed ID: 9054898
[TBL] [Abstract][Full Text] [Related]
17. IMRT optimization including random and systematic geometric errors based on the expectation of TCP and NTCP.
Witte MG; van der Geer J; Schneider C; Lebesque JV; Alber M; van Herk M
Med Phys; 2007 Sep; 34(9):3544-55. PubMed ID: 17926957
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
19. Under conditions of large geometric miss, tumor control probability can be higher for static gantry intensity-modulated radiation therapy compared to volume-modulated arc therapy for prostate cancer.
Balderson M; Brown D; Johnson P; Kirkby C
Med Dosim; 2016; 41(2):180-5. PubMed ID: 27067229
[TBL] [Abstract][Full Text] [Related]
20. Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate.
Song W; Schaly B; Bauman G; Battista J; Van Dyk J
Med Phys; 2005 Jul; 32(7Part1):2193-2203. PubMed ID: 28493587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
